How should I manage a total cholesterol of 264 mg/dL and triglycerides of 284 mg/dL?

Management of Total Cholesterol 264 mg/dL and Triglycerides 284 mg/dL

Initiate statin therapy immediately as first-line pharmacologic treatment, combined with aggressive therapeutic lifestyle changes, targeting an LDL-C <100 mg/dL and non-HDL-C <130 mg/dL, with consideration for adding fibrate or niacin after achieving LDL-C goals if triglycerides remain elevated. 1

Initial Assessment and Risk Stratification

• Obtain a complete fasting lipid panel including LDL-C, HDL-C, and calculate non-HDL-C (total cholesterol minus HDL-C = your secondary target). 1
• Calculate non-HDL-C as a critical secondary target because with triglycerides of 284 mg/dL (in the 200-499 mg/dL range), non-HDL-C better reflects your atherogenic particle burden than LDL-C alone. 2, 3
• Assess your overall cardiovascular risk including presence of established atherosclerotic cardiovascular disease (ASCVD), diabetes, or 10-year estimated cardiovascular risk to determine treatment intensity. 1, 4
• Screen for secondary causes of dyslipidemia including poorly controlled diabetes, hypothyroidism, nephrotic syndrome, and medications that may elevate lipids. 2, 5

Therapeutic Lifestyle Changes (Mandatory First-Line for All Patients)

Dietary Modifications

• Reduce saturated fat to <7% of total calories and dietary cholesterol to <200 mg/day. 1, 4
• Eliminate trans-fatty acids from your diet (reduce to <1% of energy intake). 1, 6, 3
• Reduce refined carbohydrates and added sugars, as carbohydrate restriction can lower triglycerides by 10-20%. 2
• Add plant stanols/sterols (2 g/day) and viscous fiber (≥10 g/day) to further lower LDL-C. 1, 4, 2
• Increase omega-3 fatty acid intake through fish (≥2 servings/week) or fish oil capsules; for your triglyceride level of 284 mg/dL, use 2-4 g/day of EPA/DHA for triglyceride reduction. 1, 4, 2, 3

Alcohol and Weight Management

• Restrict alcohol to ≤1 drink/day for women and ≤2 drinks/day for men, as excess alcohol markedly raises triglycerides. 2, 3
• Achieve 5-10% body weight reduction if overweight, which can lower triglycerides by approximately 20%. 2
• Target BMI of 18.5-24.9 kg/m² and waist circumference <40 inches (men) or <35 inches (women). 2

Physical Activity

• Perform 30-60 minutes of moderate-intensity aerobic activity on most days, preferably daily. 4, 2, 3
• Include resistance training approximately 2 days per week. 2

Pharmacologic Treatment Algorithm

Step 1: Statin Therapy (Primary Intervention)

• Initiate statin therapy immediately regardless of baseline LDL-C, as statins are the only cholesterol-lowering drug class with proven cardiovascular mortality benefit. 1, 6, 3
• Use moderate-to-high intensity statin to achieve LDL-C <100 mg/dL; further reduction to <70 mg/dL is reasonable for additional risk reduction, especially if you have established ASCVD or diabetes. 1, 4, 6
• Target non-HDL-C <130 mg/dL as your secondary goal with triglycerides in the 200-499 mg/dL range; further reduction to <100 mg/dL is reasonable for very high-risk patients. 1, 6, 3
• Statins will modestly reduce your triglycerides (typically 15-30% reduction) while primarily lowering LDL-C. 3, 5

Step 2: Adding Fibrate or Niacin (After LDL-C Lowering)

• If triglycerides remain 200-499 mg/dL despite statin therapy, consider adding a fibrate (fenofibrate preferred over gemfibrozil) or niacin to further lower triglycerides and non-HDL-C. 1, 6, 3
• Fenofibrate is preferred over gemfibrozil when combining with statins because gemfibrozil carries higher myopathy risk. 3
• Niacin can be added after LDL-C lowering at doses of 750-2,000 mg/day, though it may raise blood glucose and requires diabetes medication adjustment if you have diabetes. 1, 2, 3
• When combining high-dose statin with fibrate, keep statin dose relatively low to minimize severe myopathy risk. 1, 6, 3

Step 3: Intensification Options

• More intense LDL-C-lowering therapy (higher statin dose or adding ezetimibe) is the preferred first option to reduce non-HDL-C. 1, 3
• Combination therapy with statin plus ezetimibe or bempedoic acid should be considered for high-risk individuals who need lower LDL-C. 7

Critical Safety Considerations and Contraindications

• Do NOT use bile acid sequestrants when triglycerides exceed 200 mg/dL, as they are relatively contraindicated and can paradoxically raise triglyceride levels. 1, 2, 3
• Do NOT substitute over-the-counter niacin for prescription niacin without physician oversight and monitoring. 1, 2
• Do NOT combine gemfibrozil with statins; use fenofibrate instead due to lower myopathy risk. 3
• Monitor for myopathy symptoms (muscle pain, weakness) when using statin-fibrate combinations, especially with renal impairment. 3
• Omega-3 dietary supplements (combined EPA/DHA) lack proven ASCVD risk reduction benefit and should not be relied upon for cardiovascular protection. 3

Pancreatitis Risk Assessment

• Your triglyceride level of 284 mg/dL does NOT pose immediate pancreatitis risk, as this occurs primarily with levels ≥500 mg/dL. 3, 5
• If triglycerides rise to ≥500 mg/dL, initiate fibrate or niacin BEFORE LDL-lowering therapy to prevent pancreatitis. 1, 4, 6, 3

Monitoring and Follow-Up

• Reassess fasting lipid panel 4-12 weeks after initiating lifestyle changes or medication adjustments to evaluate response. 2, 3
• For hospitalized patients with acute coronary syndrome, lipid-lowering medications should be initiated before discharge. 1, 6
• Optimize glycemic control if diabetic, as improved glucose management markedly lowers triglycerides. 2, 3
• Adjust therapy based on achievement of LDL-C <100 mg/dL and non-HDL-C <130 mg/dL targets. 1, 3

Common Pitfalls to Avoid

• Do NOT delay statin initiation while attempting lifestyle changes alone; start both simultaneously for patients with your lipid profile. 1
• Do NOT add fibrate or niacin before addressing LDL-C (unless triglycerides are ≥500 mg/dL) to avoid unnecessary myopathy risk. 2, 3
• Do NOT overlook secondary causes such as poorly controlled diabetes, as optimizing glycemic control can substantially lower triglycerides. 2, 3
• Do NOT use high-dose statin with fibrate without reducing statin dose to minimize myopathy risk. 1, 6, 3